BIO vs. SNY: Bio-Rad Laboratories vs. Sanofi Stock Comparison
How do Bio-Rad Laboratories (BIO) and Sanofi (SNY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Bio-Rad Laboratories (BIO) and Sanofi (SNY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIO is classified in Life Sciences Tools & Services while SNY is classified in Pharmaceuticals.
Bio-Rad Laboratories (BIO) trades as ordinary local shares, while Sanofi (SNY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | BIO | SNY |
|---|---|---|
| Name | Bio-Rad Laboratories Inc. | Sanofi ADR |
| Country/Region | United States | France |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| GICS Sub-Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 10.26 billion USD | 112.71 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | February 27, 1980 | July 1, 2002 |
| Security Type | Common Stock | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BIO | SNY |
|---|---|---|
| Total Return (1Y) | 28.31% | 2.73% |
| Total Return (3Y, Annualized) | 8.52% | 6.89% |
| Total Return (5Y, Annualized) | -11.74% | 3.16% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | BIO | SNY |
|---|---|---|
| Volatility (1Y, Annualized) | 36.50% | 23.60% |
| Beta (5Y) | 1.03 | 0.28 |
| Max Drawdown (5Y) | -72.24% | -33.52% |
| Avg. Volume (3M) | 250.78K | 3.29M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BIO | SNY |
|---|---|---|
| Sharpe Ratio (1Y) | 0.66 | -0.07 |
| Sortino Ratio (1Y) | 0.98 | -0.10 |
Profitability
ROE (TTM)
Bio-Rad Laboratories (BIO) at 14.27% sits in the top ROE quartile, while Sanofi (SNY) at 5.72% is closer to the peer norm — stronger capital efficiency for BIO.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.27%
- Max
- 109.18%
- BIO
- 14.27%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.72%
- Max
- 109.18%
- Q3
- 6.23%
- SNY
- 5.72%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Bio-Rad Laboratories (BIO) at 39.45% keeps the most of each sales dollar — above its industry’s net margin range — and Sanofi (SNY) at 8.20% also retains a top-quartile share.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
39.45%
- BIO
- 39.45%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.20%
- Max
- 18.05%
- SNY
- 8.20%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Sanofi (SNY) at 30.89% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO) at 11.82%, which runs around its industry’s norm.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.82%
- Max
- 83.12%
- Q3
- 14.77%
- BIO
- 11.82%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.89%
- Max
- 83.12%
- SNY
- 30.89%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | BIO | SNY |
|---|---|---|
| ROE (TTM) | 14.27% | 5.72% |
| ROA (TTM) | 1.50% | 5.31% |
| Net Margin (TTM) | 39.45% | 8.20% |
| Operating Margin (TTM) | 11.82% | 30.89% |
| Gross Margin (TTM) | 52.19% | 73.68% |
Growth
Revenue Growth
Both Bio-Rad Laboratories (BIO) at 0.65% and Sanofi (SNY) at 5.49% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: Sanofi (SNY) reports EPS growth of 39.43%, ranked against its industry; Bio-Rad Laboratories (BIO) has no EPS growth figure this period.
Growth Metrics
| Metric | BIO | SNY |
|---|---|---|
| Revenue Growth (YoY) | 0.65% | 5.49% |
| Revenue Growth (3Y CAGR) | -2.68% | 4.82% |
| EPS Growth (YoY) | -- | 39.43% |
| EPS Growth (3Y CAGR) | -- | 6.02% |
Financial Strength
Current Ratio (MRQ)
Bio-Rad Laboratories (BIO) at 3.18 keeps current ratio within its industry’s typical mid-range, while Sanofi (SNY) at 1.12 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for SNY.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.18
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- BIO
- 3.18
- Q1
- 2.47
- Min
- 0.10
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.12
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- SNY
- 1.12
- Min
- 0.10
Debt / Equity (MRQ)
Both Bio-Rad Laboratories (BIO) at 0.18 and Sanofi (SNY) at 0.27 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.18
- Max
- 1.42
- Q3
- 0.65
- BIO
- 0.18
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.27
- Max
- 1.42
- Q3
- 0.65
- SNY
- 0.27
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BIO | SNY |
|---|---|---|
| Current Ratio (MRQ) | 3.18 | 1.12 |
| Debt / Equity (MRQ) | 0.18 | 0.27 |
| Net Debt / EBITDA | -0.73 | 0.96 |
Dividends
Dividend Yield (TTM)
Neither Bio-Rad Laboratories (BIO) nor Sanofi (SNY) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- SNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Sanofi (SNY) reports payout ratio above 100% at 119.86%, meaning dividends exceeded current-period earnings; Bio-Rad Laboratories (BIO) pays no dividend (payout 0.00%).
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
119.86%
- SNY
- 119.86%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BIO | SNY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 119.86% |
Valuation
P/E Ratio (TTM)
Bio-Rad Laboratories (BIO) at 10.14 sits in the cheaper P/E ratio quartile, while Sanofi (SNY) at 23.40 is closer to its industry’s usual earnings multiple — a discount for BIO, though growth and earnings durability still matter.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.14
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- BIO
- 10.14
- Min
- 0.07
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.40
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- SNY
- 23.40
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Sanofi (SNY) at 2.21 sits in the cheaper P/S ratio quartile while Bio-Rad Laboratories (BIO) at 3.96 prices around its industry’s middle — SNY costs less per dollar of sales, though read it alongside growth and margins.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.96
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- BIO
- 3.96
- Q1
- 3.01
- Min
- 0.01
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.21
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- SNY
- 2.21
- Min
- 0.01
P/B Ratio (MRQ)
Relative to net asset value, both Bio-Rad Laboratories (BIO) at 1.35 and Sanofi (SNY) at 1.38 look inexpensive, sitting in the lower P/B ratio quartile of their industries.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- BIO
- 1.35
- Min
- -5.59
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.38
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- SNY
- 1.38
- Min
- -5.59
Valuation Metrics
| Metric | BIO | SNY |
|---|---|---|
| P/E Ratio (TTM) | 10.14 | 23.40 |
| P/S Ratio (TTM) | 3.96 | 2.21 |
| P/B Ratio (MRQ) | 1.35 | 1.38 |
| Free Cash Flow Yield (TTM) | 2.65% | 7.17% |